Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection

Drug Safety

Volumn 26, Issue 4, 2003, Pages 283-291

  Lacaze Masmonteil, Thierry ^a   Seidenberg, Juergen ^b   Mitchell, Ian ^c   Cossey, Veerle ^d   Cihar, Martin ^e   Csader, Michal ^f   Baarsma, Rienk ^g   Valido, Marques ^h   Pollack, Paul F ⁱ   Groothuis, Jessie R ⁱ   Allegaert, Karel ^d   Lombet, Jacques ^j   Haumont, Dominique ^k   Plaskie, Katleen ^k   Davies, H Dele ^c   Sauve, Reginald S ^l   Langley, Joanne M ^m   Liska, Karel ⁿ   Andre, Patrick ^a   Lequien, Pierre ^q   Kacet, Nadine ^q   Lapeyre, Fabrice ^q   Wickenburg Ennen, Barbara ^b   Nolte, Helga ^b   Harding, Peter Andreas ^b   Ramos, Sandra ^o   Carolino, Margarida ^o   Marques, Antónia ^p   more..

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b Elisabeth Kinderkrankenhaus   (Germany)

^c ALBERTA CHILDREN'S HOSPITAL   (Canada)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^f Children Hospital   (Slovakia)

^g MEDISCH SPECTRUM TWENTE   (Netherlands)

^h Hospital Dr Alfredo da Costa   (Portugal)

ⁱ ABBOTT LABORATORIES   (United States)

^j Centre Hospitalier Regional de La Citadelle   (Belgium)

^k SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^l UNIVERSITY OF CALGARY   (Canada)

^m DALHOUSIE UNIVERSITY   (Canada)

ⁿ CHARLES UNIVERSITY   (Czech Republic)

^o HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^p Maternidade Dr Alfredo da Costa   (Portugal)

^q Hop Antoine Beclere ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; PALIVIZUMAB;

ANOREXIA; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; ASTHMA; ATAXIA; BRONCHIOLITIS; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG FEVER; EPISTAXIS; ESOPHAGITIS; FEMALE; GASTROENTERITIS; GASTROINTESTINAL INFECTION; HOSPITAL INFECTION; HUMAN; INFANT; INFECTION RISK; INFLUENZA; LETHARGY; LOWER RESPIRATORY TRACT INFECTION; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OTITIS MEDIA; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RHINITIS; ROTAVIRUS; SEASON; SHOCK; STRIDOR; VIRUS INFECTION; VOMITING;

ANTIBODIES, MONOCLONAL; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; SEASONS; STATISTICS, NONPARAMETRIC;

EID: 0037232387     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326040-00005     Document Type: Article

References (24)

1. Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. Philadelphia (PA): Saunders, 1998: 2084-111
2. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999 Oct 20; 282 (15): 1440-6
3. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 4th ed. New York (NY): Churchill Livingstone, 1995: 1501-19
4. Groothuis JR, Salbenblatt CK, Lauer BA. Severe respiratory syncytial virus infection in older children. Am J Dis Child 1990 Mar; 144 (3): 346-8
5. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988 Aug; 82 (2): 199-203
6. Boyce TG, Mellen BG, Mitchel EF, et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000 Dec; 137 (6): 865-70
7. Hall CB, Powell KR, Schnabel KC, et al. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial virus infection. J Pediatr 1988 Aug; 113 (2): 266-71
8. MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med 1982 Aug; 307 (7): 397-400
9. Piedra PA. Respiratory syncytial virus vaccines: recent developments. Pediatr Infect Dis J 2000 Aug; 19 (8): 805-8
10. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997 Nov; 176 (5): 1215-24
11. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998 Sep; 102 (3 Pt 1): 531-7
12. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998 Nov; 102 (5): 1211-6
13. Carbonell-Estraney X, Giuffré L, Kimpen JLL, et al. Guidelines for the use of Synagis® (palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion. Infect Med 1999 Dec; 16 Suppl. G: 29-33
14. ICH Harmonized Tripartite Guideline for Good Clinical Practice (E6). International Conference on Harmonization Website. Available from URL: http://www.ifpma.org/ich5e.html# GCP [Accessed 1999 Sep 10]
15. Gardner PS, McQuillin J. Rapid virus diagnosis. 2nd ed. London: Butterworth and Co Ltd, 1980
16. Hall CB, Douglass Jr RG. Clinically useful method for the isolation of respiratory syncytial virus. J Infect Dis 1975 Jan; 131 (1): 1-5
17. Mcintosh K, Hendry RM, Fahnestock ML, et al. Enzyme-linked immunosorbent assay for detection of respiratory syncytial virus infection: application to clinical samples. J Clin Microbiol 1982 Aug; 16 (2): 329-33
18. Subramanian KNS, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 1998; 17 (2): 110-5
19. Null DM, Connor EM. Evaluation of immunogenicity and safety in children receiving palivizumab for a second RSV season [abstract]. Pediatr Res 1999; 45 (Pt 2 of 2): 170A
20. Gross R. Analytical report, evaluation of MEDI-493. Immunogenicity in children (a phase II/IV multicenter study, W99-310). MedImmune Jun 2001. (Data on file)
21. Abman SH, Groothuis JR. Pathophysiology and treatment of bronchopulmonary dysplasia: current issues. Pediatr Clin North Am 1994 Apr; 41 (2): 277-315
22. Cavalier S, Escobar GJ, Fernbach SA, et al. Postdischarge utilization of medical services by high-risk infants: experience in a large managed care organization. Pediatarics 1996 May; 97 (5): 693-9
23. Parker RA, Lindstrom DP, Cotton RB. Improved survival accounts for most, but not all, of the increase in bronchopulmonary dysplasia. Pediatrics 1992 Nov; 90 (5): 663-8
24. Law BJ, MacDonald N, Langley J, et al. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: what are we trying to prevent? J Paediatr Child Health 1998 Nov/Dec; 3 (6): 402-4